Biogen Inc. (BIIB)
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody.
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024.
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodman - Leerink Partners Marc Goodman Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America.
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 45th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen.
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact.
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Biogen Analysts Lower Their Forecasts After Q4 Results
Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
